Comparison of CD4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors for patients with advanced HR+/HER2‐ Breast cancer: A network meta‐analysis of 19 RCTs. - Wang, Lida; Da, Huo; Li, Xiulian; Ran, Xuehong; Wu, Wei; Sheng, Zhixin (Breast Journal, 2020)